Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Fms-like tyrosine kinase 3/ITD is a relevant marker for acute myeloid leukemia prognosis
September 20th, 2006
Fms-like tyrosine kinase 3/ITD is a relevant marker for acute myeloid leukemia prognosis. According to recent research from the Netherlands, "In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients." "One D835 point mutation was found in an initial pediatric AML sample. Fms-like tyrosine kinase 3/ITDs were present in 21 initial and 22 relapse samples (26.3 and 27.5%, respectively). "Interestingly,...
Source: Biotech Week (2006-09-20)
|
